Red Light Holland Reports First Quarter 2024 Results
Cash balance of $17.5 million as at June 30, 2023Revenue of $1.2 million (vs 2022: $0.8 million, an increase of...
Pharmaceutical
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC")...
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIALNEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMEDHAMBURG, GERMANY / ACCESSWIRE / August 29, 2023...
Bionxt Solutions Announces Closing of First Tranche of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, BC / ACCESSWIRE /...
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
Napo Pharmaceuticals, a Jaguar family company, reported completion August 17 of last patient last visit for its pivotal Phase 3...
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism
CHARLOTTESVILLE, Va., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...
NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million to...
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the...
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol...
PetVivo Holdings, Inc. Achieves National Distribution of Spryng to More than 500 Veterinary Clinics in 49 States
MINNEAPOLIS, MN, US, Aug. 28, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging...
Rhythm Pharmaceuticals to Present at Investor Conferences in September
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel...
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed...
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical...
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an...
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical...
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204...
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced...
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated...